seen from Malaysia
seen from United States
seen from Germany
seen from China
seen from China
seen from China
seen from United Kingdom
seen from Germany
seen from United States
seen from France
seen from Brazil
seen from Netherlands
seen from Malaysia
seen from United States
seen from China
seen from United States
seen from Ireland
seen from New Zealand
seen from Germany
seen from United Kingdom
Sanger Sequencing Service Market: Current Trends, Key Players, and Future Prospects
Sanger sequencing, a method pioneered by Frederick Sanger, is used for determining the nucleotide sequence of DNA. It remains a foundational technique in genomics, providing high accuracy in sequencing short DNA fragments. This market encompasses services that offer Sanger sequencing for various applications, including clinical diagnostics, research, and pharmaceutical development.
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Sanger Sequencing Platform and HLA Typing Kits
Life Technologies today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 3500 Dx Genetic Analyzers and SeCore® HLA typing kits. The development represents additional execution against the company’s strategy to become a leader in the diagnostics market by offering both novel clinical assays and best- in-class molecular testing products.
“This successful application for our Sanger sequencer with HLA typing kits is further demonstration of Life Technologies’ track record in obtaining FDA regulatory clearance for genetic analysis in the clinical market,” said Greg Lucier, chairman and chief executive officer of Life Technologies. “We will continue to aggressively pursue a regulatory pathway for our leading technologies in the clinical space, including next-generation sequencing.”
Read More
